Financial reports
10-Q
2016 Q2
Quarterly report
4 Aug 16
10-Q
2016 Q1
Quarterly report
10 May 16
10-K
2015 FY
Annual report
4 Mar 16
10-Q
2015 Q3
Quarterly report
6 Nov 15
10-Q
2015 Q2
Quarterly report
5 Aug 15
10-Q
2015 Q1
Quarterly report
12 May 15
10-K
2014 FY
Annual report
31 Mar 15
10-Q
2014 Q3
Quarterly report
12 Nov 14
Current reports
8-K
Termination of a Material Definitive Agreement
25 Oct 16
8-K
Entry into a Material Definitive Agreement
14 Sep 16
8-K
Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results
3 Aug 16
8-K
Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
27 Jul 16
8-K
Entry into a Material Definitive Agreement
30 Jun 16
8-K
Submission of Matters to a Vote of Security Holders
26 May 16
8-K
Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results
10 May 16
8-K
Vitae Pharmaceuticals Prices Public Offering of Common Stock
24 Mar 16
8-K
Vitae Pharmaceuticals Proposes Public Offering of Common Stock
23 Mar 16
8-K
Regulation FD Disclosure
16 Mar 16
Registration and prospectus
15-12B
Securities registration termination
4 Nov 16
25-NSE
Exchange delisting
25 Oct 16
POS AM
Prospectus update (post-effective amendment)
25 Oct 16
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Oct 16
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Oct 16
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Oct 16
SC 14D9/A
Tender offer solicitation (amended)
25 Oct 16
SC TO-T/A
Third party tender offer statement (amended)
25 Oct 16
SC 14D9/A
Tender offer solicitation (amended)
17 Oct 16
SC TO-T/A
Third party tender offer statement (amended)
17 Oct 16
Other
EFFECT
Notice of effectiveness
28 Oct 16
EFFECT
Notice of effectiveness
5 Nov 15
CORRESP
Correspondence with SEC
4 Nov 15
EFFECT
Notice of effectiveness
22 Jan 15
CT ORDER
Confidential treatment order
25 Sep 14
EFFECT
Notice of effectiveness
24 Sep 14
CORRESP
Correspondence with SEC
23 Sep 14
CORRESP
Correspondence with SEC
23 Sep 14
CORRESP
Correspondence with SEC
23 Sep 14
UPLOAD
Letter from SEC
23 Sep 14
Ownership
SC 13G/A
Vitae Pharmaceuticals, Inc
14 Feb 17
SC 13G/A
Vitae Pharmaceuticals, Inc
14 Feb 17
4
JOHN M. LEONARD
25 Oct 16
4
Scott Applebaum
25 Oct 16
4
DANIEL M JUNIUS
25 Oct 16
4
Arthur Fratamico
25 Oct 16
4
Carole Sable
25 Oct 16
4
Karen Bernstein
25 Oct 16
4
GINO SANTINI
25 Oct 16
4
Jeffrey S. Hatfield
25 Oct 16